Index
1 Noninvasive Delivery Vaccine Market Overview
1.1 Product Overview and Scope of Noninvasive Delivery Vaccine
1.2 Noninvasive Delivery Vaccine Segment by Type
1.2.1 Global Noninvasive Delivery Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Oral Vaccine
1.2.3 Nasal Spray Vaccine
1.3 Noninvasive Delivery Vaccine Segment by Application
1.3.1 Global Noninvasive Delivery Vaccine Market Value by Application: (2023-2029)
1.3.2 Public
1.3.3 Private
1.4 Global Noninvasive Delivery Vaccine Market Size Estimates and Forecasts
1.4.1 Global Noninvasive Delivery Vaccine Revenue 2018-2029
1.4.2 Global Noninvasive Delivery Vaccine Sales 2018-2029
1.4.3 Global Noninvasive Delivery Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Noninvasive Delivery Vaccine Market Competition by Manufacturers
2.1 Global Noninvasive Delivery Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Noninvasive Delivery Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Noninvasive Delivery Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Noninvasive Delivery Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Noninvasive Delivery Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Noninvasive Delivery Vaccine, Product Type & Application
2.7 Noninvasive Delivery Vaccine Market Competitive Situation and Trends
2.7.1 Noninvasive Delivery Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Noninvasive Delivery Vaccine Players Market Share by Revenue
2.7.3 Global Noninvasive Delivery Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Noninvasive Delivery Vaccine Retrospective Market Scenario by Region
3.1 Global Noninvasive Delivery Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Noninvasive Delivery Vaccine Global Noninvasive Delivery Vaccine Sales by Region: 2018-2029
3.2.1 Global Noninvasive Delivery Vaccine Sales by Region: 2018-2023
3.2.2 Global Noninvasive Delivery Vaccine Sales by Region: 2024-2029
3.3 Global Noninvasive Delivery Vaccine Global Noninvasive Delivery Vaccine Revenue by Region: 2018-2029
3.3.1 Global Noninvasive Delivery Vaccine Revenue by Region: 2018-2023
3.3.2 Global Noninvasive Delivery Vaccine Revenue by Region: 2024-2029
3.4 North America Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.4.1 North America Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.4.3 North America Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.5.1 Europe Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.5.3 Europe Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.7.1 Latin America Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Noninvasive Delivery Vaccine Sales by Type (2018-2029)
4.1.1 Global Noninvasive Delivery Vaccine Sales by Type (2018-2023)
4.1.2 Global Noninvasive Delivery Vaccine Sales by Type (2024-2029)
4.1.3 Global Noninvasive Delivery Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Noninvasive Delivery Vaccine Revenue by Type (2018-2029)
4.2.1 Global Noninvasive Delivery Vaccine Revenue by Type (2018-2023)
4.2.2 Global Noninvasive Delivery Vaccine Revenue by Type (2024-2029)
4.2.3 Global Noninvasive Delivery Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Noninvasive Delivery Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Noninvasive Delivery Vaccine Sales by Application (2018-2029)
5.1.1 Global Noninvasive Delivery Vaccine Sales by Application (2018-2023)
5.1.2 Global Noninvasive Delivery Vaccine Sales by Application (2024-2029)
5.1.3 Global Noninvasive Delivery Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Noninvasive Delivery Vaccine Revenue by Application (2018-2029)
5.2.1 Global Noninvasive Delivery Vaccine Revenue by Application (2018-2023)
5.2.2 Global Noninvasive Delivery Vaccine Revenue by Application (2024-2029)
5.2.3 Global Noninvasive Delivery Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Noninvasive Delivery Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Noninvasive Delivery Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Noninvasive Delivery Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Noninvasive Delivery Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Noninvasive Delivery Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute Noninvasive Delivery Vaccine Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Valneva Noninvasive Delivery Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai United Cell Noninvasive Delivery Vaccine Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bibcol Noninvasive Delivery Vaccine Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PaxVax Noninvasive Delivery Vaccine Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vabiotech Noninvasive Delivery Vaccine Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Noninvasive Delivery Vaccine Description and Business Overview
6.11.3 Tiantan Biological Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Biological Noninvasive Delivery Vaccine Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Noninvasive Delivery Vaccine Description and Business Overview
6.12.3 EuBiologics Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 EuBiologics Noninvasive Delivery Vaccine Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Noninvasive Delivery Vaccine Description and Business Overview
6.13.3 Panacea Biotec Ltd Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Panacea Biotec Ltd Noninvasive Delivery Vaccine Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Noninvasive Delivery Vaccine Description and Business Overview
6.14.3 Bio-Med Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bio-Med Noninvasive Delivery Vaccine Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
6.16 AstraZeneca
6.16.1 AstraZeneca Corporation Information
6.16.2 AstraZeneca Noninvasive Delivery Vaccine Description and Business Overview
6.16.3 AstraZeneca Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.16.4 AstraZeneca Noninvasive Delivery Vaccine Product Portfolio
6.16.5 AstraZeneca Recent Developments/Updates
6.17 Cipla
6.17.1 Cipla Corporation Information
6.17.2 Cipla Noninvasive Delivery Vaccine Description and Business Overview
6.17.3 Cipla Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Cipla Noninvasive Delivery Vaccine Product Portfolio
6.17.5 Cipla Recent Developments/Updates
6.18 BCHT
6.18.1 BCHT Corporation Information
6.18.2 BCHT Noninvasive Delivery Vaccine Description and Business Overview
6.18.3 BCHT Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.18.4 BCHT Noninvasive Delivery Vaccine Product Portfolio
6.18.5 BCHT Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Noninvasive Delivery Vaccine Industry Chain Analysis
7.2 Noninvasive Delivery Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Noninvasive Delivery Vaccine Production Mode & Process
7.4 Noninvasive Delivery Vaccine Sales and Marketing
7.4.1 Noninvasive Delivery Vaccine Sales Channels
7.4.2 Noninvasive Delivery Vaccine Distributors
7.5 Noninvasive Delivery Vaccine Customers
8 Noninvasive Delivery Vaccine Market Dynamics
8.1 Noninvasive Delivery Vaccine Industry Trends
8.2 Noninvasive Delivery Vaccine Market Drivers
8.3 Noninvasive Delivery Vaccine Market Challenges
8.4 Noninvasive Delivery Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer